

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated antibody, ~~antibody derivative~~, or antigen-binding fragment thereof polypeptide that binds to an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

2. (Currently Amended) An isolated antibody, ~~antibody derivative~~, or antigen-binding fragment thereof polypeptide that has the same epitope specificity as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

3. (Currently Amended) An isolated antibody, ~~antibody derivative~~, or antigen-binding fragment thereof polypeptide that crossblocks binding of the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

4. (Currently Amended) The isolated antibody, ~~antibody derivative~~, or antigen-binding fragment thereof polypeptide of claim 1, ~~2, or 3~~, wherein the antibody is a humanized ~~monoclonal~~ antibody.

5. (Currently amended) The isolated antibody, ~~antibody derivative~~, or antigen-binding fragment thereof polypeptide of claim 1, ~~2 or 3~~, wherein the antibody is a fully human antibody.

6. (Currently Amended) A conjugate comprising the isolated antibody, ~~antibody derivative~~, or antigen-binding fragment thereof ~~polypeptide~~ of claim 1, 2 or 3 linked to a detectable label.

7. (Currently Amended) A conjugate or fusion polypeptide comprising the isolated antibody, ~~antibody derivative~~, or antigen-binding fragment thereof ~~polypeptide~~ of claim 1, 2 or 3 and a toxin moiety.

8. (Original) An antibody produced by the hybridoma deposited with ATCC under Accession No. PTA-3350.

9. (Original) Hybridoma ABE3, deposited with ATCC under Accession No. PTA-3350.

10. (Cancelled)

11. (Currently Amended) A composition comprising the isolated antibody, ~~antibody derivative~~, or antigen-binding fragment thereof ~~polypeptide~~ of claim 1, 2 or 3 and a pharmaceutically acceptable carrier.

12-22. (Cancelled)

23. (New) The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to an epitope within the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

24. (New) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody is a humanized antibody.

25. (New) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody is a humanized antibody.

26. (New) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody is a humanized antibody.

27. (New) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody is a fully human antibody.

28. (New) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody is a fully human antibody.

29. (New) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody is a fully human antibody.

30. (New) The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody is a monoclonal antibody.

31. (New) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody is a monoclonal antibody.

32. (New) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody is a monoclonal antibody.

33. (New) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody is a monoclonal antibody.

34. (New) The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody is a single chain antibody.

35. (New) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody is a single chain antibody.

36. (New) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody is a single chain antibody.

37. (New) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody is a single chain antibody.

38. (New) The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an  $F_{ab}$  fragment, an  $F_{(ab')_2}$  fragment, an  $F_{ab'}$  fragment, an  $F_{sc}$  fragment, or an  $F_v$  fragment.

39. (New) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an  $F_{ab}$  fragment, an  $F_{(ab')_2}$  fragment, an  $F_{ab'}$  fragment, an  $F_{sc}$  fragment, or an  $F_v$  fragment.

40. (New) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an  $F_{ab}$  fragment, an  $F_{(ab')_2}$  fragment, an  $F_{ab'}$  fragment, an  $F_{sc}$  fragment, or an  $F_v$  fragment.

41. (New) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an  $F_{ab}$  fragment, an  $F_{(ab')_2}$  fragment, an  $F_{ab'}$  fragment, an  $F_{sc}$  fragment, or an  $F_v$  fragment.